Inositol is an important precursor for second messenger synthesis and
has been reported to be reduced by lithium treatment in rat brain and
in human CSF in depression. An open trial of 6 g/day in 11 depressed p
atients resistant to previous treatment led to major improvement in ni
ne patients. The enzyme synthesizing inositol has been reported to be
elevated in schizophrenia, suggesting an attempted compensation for po
ssible inositol deficiency. A controlled double-blind crossover trial
in 10 chronic schizophrenic patients of 6 g/day of inositol for 30 day
s did not reveal any benefit.